Keywords
Biological medicines
TNF-Alpha inhibitors
How to Cite
Copyright © | All rights reserved.
The journal holds the exclusive copyright for the publication of this article under the terms of Brazilian law 9610/98.
Partial reproduction
The use of parts of the texts, figures and questionnaire of the article is free, being mandatory the citation of the authors and journal.
Total reproduction
It is expressly prohibited and must be authorized by the journal.
Abstract
Objective: Review the literature on the efficacy of immunobiologicals in the treatment of psoriasis, identifying the main drugs used, their therapeutic outcomes, adverseeffects, and the impact on patients´ quality of life. Literature review: The results demonstrated that immunobiologicals are highly effective in the treatment of moderate to severe psoriasis, improving the symptoms and quality of life of the patient. However, it is necessary to pay attention to contraindications and comorbidities that may alter the prognosis of the treatment. Final considerations: Biologic agents have proven effective in the treatment of moderate to severe psoriasis acting specifically on the immune system and promoting clinical improvement and enhanced quality of life for patients. Recent studies confirm their superiority over other therapies but emphasize the importance of considering contraindications, comorbidities, and individualized treatment approaches. There is a notable lack of research involving age groups outside of adulthood, which limits therapeutic options for children, adolescents, and the elderly. Additionally, the high-cost limited availability of these medication through the Brazilian Unified Health System (SUS) hinder acces, highlighting the need por public policies tha expand availability and reduce disparities in psoriasis treatment.
References
BAKIRTZI K, et al. Elderly patients with psoriasis: long-term efficacy and safety of modern treatments. Journal of Dermatological Treatment, 2022; 33(3): 1339-1342.
BETANCOURT OSM, et al. Comorbilidades na psoríase: revisão bibliográfica. Revista Foco, 2023; 16(8): 2754.
BRANDÃO GVC, et al. Caracterização clínica, fragilidade física e depressão em idosos com psoríase oriundos de centro de referência no Brasil: estudo transversal. Anais Brasileiros de Dermatologia, 2024; 99(1): 19-26.
DI CAPRIO R, et al. Preocupações de segurança com os tratamentos atuais para psoríase em idosos. Opinião de Especialista sobre Segurança de Medicamentos, 2020; 19(4): 523–531.
DUQUE CM, et al. Monitoramento clínico-laboratorial de pacientes portadores de psoríase em uso de imunobiológicos. LAES/HAES, 2020; 244: 70-94.
FERNANDES MO, et al. Efeitos adversos do uso de imunobiológicos no tratamento da psoríase: uma revisão integrativa. Revista de Medicina, 2018; 97(5): 486-492.
FERRUCHI R. A resposta dos imunobiológicos na psoríase infantil. Jornal BWS, 2023; 6: 1-12.
GRIFFITHS CEM, et al. Psoriasis. The Lancet, 2021; 397(10281): 1301–1315.~
HUANG L, et al. Stigma and psychological health in psoriasis patients based on the dual-factor model of mental health: thechain mediating roles of social appearance anxiety and alexithymia. Frontiers in psychiatry, 2024; 15: 1499714.
KAMIYA K, et al. Fatores de risco para o desenvolvimento da psoríase. RevistaInternacional de CiênciasMoleculares, 2019; 20(18): 43-47.
LEE H e KIM M. Challenges and future trends in the treatment of psoriasis. International Journal of Molecular Sciences, 2023; 24(17): 13313.
LEONE GM, et al. Past, present and (foreseeable) future of biological anti-TNF alpha therapy. Journal of Clinical Medicine, 2023; 12(4): 16-30.
MAHÉ E. Childhood psoriasis. European Journal of Dermatology, 2016; 26: 537-548.
MOTA CCF, et al. Therapeutic response and survival time of immunobiologicals in patients with moderate to severe psoriasis. Anais Brasileiros de Dermatologia, 2022; 97: 112-115.
NGUYEN QD, et al. The use of TNFα inhibitors in treating pediatric skin disorders. Pediatric Drugs, 2020; 22(3): 311-319.
PALHANO ACM, et al. Unmet need for and impact of adopting immunobiological drugs for moderate to severe plaque psoriasis in a pediatric population. Einstein (São Paulo), 2024; 22: 413.
PAN J, et al. Use of biologics in patients with psoriasis – a retrospective analysis based on real-world data. Skin Research and Technology, 2024; 30(1): 13550.
PASCOAL GN, et al. Psoríase: aspectos etiopatogênicos, métodos diagnósticos e condutas terapêuticas. Revista Brasileira de Revisão de Saúde, 2023; 3: 13189–13206.
PEREIRA FCG e DA SILVA TMB. Tratamentos sistêmicos de Psoríase e a comparação do perfil de eficácia: uma revisão da literatura. COGNITIONIS ScientificJournal, 2024; 7(2): 470-470.
PSORÍASE. SBD - Sociedade Brasileira de Dermatologia, 2021. Disponível em: https ://www.sbd.org.br/ doencas/psoriase/. Acesso em: 10 set. 2024.
RAHARJA A, et al. Psoríase: um breve panorama. Medicina Clínica, 2021; 21(3): 170.
RENDON A e SCHÄKEL K. Psoriasis pathogenesis and treatment. International Journal of Molecular Sciences, 2019; 20(6): 1475.
RICCERI F, et al. “Elderly psoriatic patients under biological therapies: an Italian experience.” Journal of the European Academyof Dermatology and Venereology: 2019; 33(1): 143-146.
RODRIGUES KBB. Os Tratamentos da Psoríase. BWS Journal, 2022; 5: 1-10.
ROMITI R, et al. Infecções na era dos imunobiológicos. Anais Brasileiros de Dermatologia, 2024; 2: 167-180.
SBD. Consenso brasileiro de psoríase 2020: algoritmo de tratamento da Sociedade Brasileira de Dermatologia. Rio de Janeiro: Sociedade Brasileira de Dermatologia, 2020.